Abstract
Objective
The objective was to investigate the prevalence of incidental fluorine-18 fluorodeoxyglucose
(FDG) uptake in positron emission tomography/computed tomography.
Methods
A total of 11,239 male nonprostate disease patients were included retrospectively.
Results
The prevalence of incidental prostate FDG uptake was approximately 1.8%. Among 198
incidental lesions, 100 patients had further examinations; 20 lesions were confirmed
to be malignant, while 80 lesions were benign. After logistic regression analysis,
age, site, and the maximum standard uptake value were the potent predictors for differentiation
of malignant prostate lesions.
Conclusion
When focal FDG uptake in the peripheral zone of prostate is detected, especially in
elderly men, further clinical evaluation is recommended.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- NCCN task force: clinical utility of PET in a variety of tumor types.J Natl Compr Canc Netw. 2009; 7: S1-S26
- Positron emission tomography/computed tomography potential pitfalls and artifacts.Curr Probl Diagn Radiol. 2009; 38: 156-169
- Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography.Nucl Med Commun. 2009; 30: 742-748
- Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images.Br J Radiol. 2010; 83: 915-920
- Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons.BJU Int. 2002; 90: 162-173
- Epidemiology of prostate cancer and treatment remarks.World J Radiol. 2012; 4: 241-246
- Role of imaging in prostate cancer.PET Clin. 2009; 4: 135-138
- Prostate cancer staging using imaging.BJU Int. 2000; 86: 123-134
- Cancer screening of healthy volunteers using whole-body 18 F-FDG-PET scans: the Nishidai clinic study.Eur J Cancer. 2007; 43: 1842-1848
- The value of 18 F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.Neoplasma. 2003; 50: 217-221
- Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18 F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects.J Clin Endocrinol Metab. 2003; 88: 4100-4104
- The roles of PET and PET/CT in the diagnosis and management of prostate cancer.Oncology. 2007; 72: 226-233
- Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review.J Urol. 2008; 179: 34-45
- Molecular positron emission tomography and PET/CT imaging in urological malignancies.Eur Urol. 2007; 51 ([discussion 1520–1521]): 1511-1520
- Technical limits of PET/CT with 18FDG in prostate cancer.Aktuelle Urol. 2006; 37: 218-221
- Diffuse FDG uptake in acute prostatitis.Clin Nucl Med. 2008; 33: 308-310
- Positron emission tomography and molecular imaging of the prostate: an update.BJU Int. 2006; 97: 923-931
- BCG-induced granulomatous prostatitis—an incidental finding on FDG PET-CT.Clin Imaging. 2012; 36: 413-415
- Solitary pulmonary nodular lung adenocarcinoma: correlation of histopathologic scoring and patient survival with imaging biomarkers.Radiology. 2012; 264: 884-893
- Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score.Oncol Rep. 2008; 20: 1561-1567
- The zonal anatomy of the prostate.Prostate. 1981; 2: 35-49
- Stromal microcalcification in prostate.Malays J Pathol. 2001; 23: 31-33
- Incidence and significance of prostatic stones in men with chronic prostatitis/chronic pelvic pain syndrome.Urology. 2007; 70: 235-238
- Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.Urology. 2004; 63: 709-715
- Metabolic imaging of untreated prostate cancer by positron emission tomography with 18 fluorine-labeled deoxyglucose.J Urol. 1996; 155: 994-998
- Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.Eur Urol. 1999; 36: 31-35
- Detection of unexpected additional primary malignancies with PET/CT.J Nucl Med. 2005; 46: 752-757
Article info
Publication history
Published online: February 10, 2014
Accepted:
January 16,
2014
Received in revised form:
December 25,
2013
Received:
October 24,
2013
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
